Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
10/07/2026 18:29
BRIEF-AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies July 10 (Reuters) - AB Science SA ABS.PA:
AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS
AB SCIENCE - DISCONTINUES PHASE 2 STUDY AB20006, PHASE 3 STUDY AB15003, PHASE 3 STUDY AB20009
AB SCIENCE - TO SEEK AUTHORIZATION TO INITIATE PHASE 4 OF AB8939, VENETOCLAX, AND AZACITIDINE COMBINATION
AB SCIENCE SA: DISCONTINUATION OF STUDIES IS NOT RELATED TO ANY SAFETY CONCERNS REGARDING MASITINIB
AB SCIENCE - TO UPDATE PROTOCOL AND SEEK AUTHORIZATION TO RESUME PHASE 3 MASITINIB STUDY IN ALS
Source text: ID:nGNX2NMZ3R
Further company coverage: ABS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041